ACELYRIN appoints Mina Kim as CEO; founder Lin steps down; cash $678.5M

ACELYRIN, Inc.

Mina Kim appointed CEO and board member effective May 9; Shao-Lee Lin steps down as CEO and from board.
Cash, cash equivalents and short-term marketable securities total $678.5M at March 31, 2024; funding into 2026 reiterated.
Izokibep Phase 3 HS trial enrollment completed (258 patients); top-line data expected Q3 2024.
Positive proof-of-concept for lonigutamab in thyroid eye disease; Phase 2b/3 trial planned H2 2024.
Company will not host Q1 2024 earnings call; 10-Q to be filed by May 14, 2024.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ron Oyston

Chief People Officer

ACELYRIN, Inc.

Effective: 2024-08-15
Filed: May 9, 2024, 7:59 PM ET

Effective on May 8, 2024, the Company and Ron Oyston mutually agreed that Mr. Oyston will step down from his position as Chief People Officer, effective August 15, 2024.

Appointed

Mina Kim

Chief Executive Officer

ACELYRIN, Inc.

Effective: 2024-05-09
Filed: May 9, 2024, 7:59 PM ET

Effective May 9, 2024, Mina Kim was appointed as the Chief Executive Officer of the Company and was appointed as a member of the Board of Directors of the Company (the “Board”).

Departed

Shao-Lee Lin

Chief Executive Officer

ACELYRIN, Inc.

Effective: 2024-05-08
Successor: Mina Kim
Filed: May 9, 2024, 7:59 PM ET

By mutual agreement of Shao-Lee Lin, M.D., Ph.D. and the Company, Dr. Lin stepped down from her position as Chief Executive Officer and as a member of the Board, effective on May 8, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ron Oyston departed as Chief People Officer at ACELYRIN, Inc..

Action: stepped down
Role: Chief People Officer

Exact text from the filing

Effective on May 8, 2024, the Company and Ron Oyston mutually agreed that Mr. Oyston will step down from his position as Chief People Officer, effective August 15, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mina Kim was appointed as Chief Executive Officer at ACELYRIN, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Effective May 9, 2024, Mina Kim was appointed as the Chief Executive Officer of the Company and was appointed as a member of the Board of Directors of the Company (the “Board”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Shao-Lee Lin departed as Chief Executive Officer at ACELYRIN, Inc..

Action: stepped down
Role: Chief Executive Officer

Exact text from the filing

By mutual agreement of Shao-Lee Lin, M.D., Ph.D. and the Company, Dr. Lin stepped down from her position as Chief Executive Officer and as a member of the Board, effective on May 8, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-134812

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.